Cancer and Personalized Medicine Companion Diagnostics Market Reviewed in 2015 Research Report

18 Nov, 2015, 07:30 ET from RnR Market Research

PUNE, India, November 18, 2015 /PRNewswire/ --

The report examines the use and market of companion diagnostics in personalized medicine and cancer therapy covering a qualitative and quantitative review of the industry, including cancer biomarker tests, pharmacogenomics tests, recurrence prediction tests, blood-based technologies, proteomics and regulatory trends.

Complete market report on companion diagnostics in personalized medicine and cancer therapy spread across 249 pages, profiling 50 companies and supported with 41 tables and 27 figures is now available at http://www.rnrmarketresearch.com/companion-diagnostics-in-personalized-medicine-and-cancer-therapy-market-report.html.

Moreover, this analysis profiles the leading companies that are developing and manufacturing companion diagnostics solutions. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market share data are also included.

Companion diagnostics (CDx) refers to a particular clinical diagnostic test that is under evaluation and is specifically linked to a known drug therapy. This linkage could be important in the therapeutic application and clinical outcome of a drug, such as with personalized medicine for oncology patients. The molecular diagnostics field plays a vital part in personalized medicine and has greatly expanded over the past twenty years, expanding by more than 20% annually compared to most other laboratory procedures. Research will continue to produce an increased understanding of disease processes, and diagnostics manufacturers will continue to expand and refine the technology and automation needed for clinical testing. Companion diagnostics, although smaller at present, is one of the fastest growing segments in the in vitro diagnostic (IVD) market. And while the concept of a drug-diagnostic combination is not new, it has only recently started to generate interest with the move of healthcare towards pharmacogenomics.

Companies Entering the Companion Diagnostics Market are 20/20 GeneSystems, Inc., Abbott Molecular, Inc., Affymetrix, Inc., Agendia BV, Agilent Technologies, Almac Group, Asuragen, Inc., Aureon Laboratories, Inc., Becton, Dickinson and Company (BD) Diagnostics-TriPath, Biodesix, Biomarker Technologies, LLC, bioMérieux, Inc., Cepheid, Inc., Cipher Genomics, diaDexus, DiagnoCure, EDP Biotech Corporation, Eisai Co., Ltd., Eli Lilly & Co., Epigenomics, Exagen Diagnostics, Inc., Exiqon, Genomic Health, Inc., Hologic, Halozyme Therapeutics, Ikonisys, Inc., Illumina, Inc., HalioDx, InterGenetics, Inc., Johnson & Johnson, LabCorp, MolecularMD Corporation, MDxHealth, Monogram Biosciences, Myriad Genetics, Inc., Novartis MDx, Nycomed (Takeda), Orion Genomics, Oxford BioTherapeutics (Formerly Oxford Genome Sciences), NanoString Technologies, QIAGEN N.V., Roche Molecular Diagnostics, Sanko Junyaku Co., Ltd. (Eisai Co., Ltd.), SensiGen, LLC (Sequenom Center for Molecular Medicine), Siemens Healthcare Diagnostics, Inc., Tosoh Biosciences Corporation, Transgenomic, Inc., Ventana Medical Systems, Inc., Vermillion, Inc. (Formerly Ciphergen) and Vertex Pharmaceuticals, Inc. Order a copy of Companion Diagnostics in Personalized Medicine and Cancer Therapy report at http://www.rnrmarketresearch.com/contacts/purchase?rname=58686.

Another and related report titled Companion Diagnostics Partnering Terms and Agreements provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the world's leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes numerous tables and figures that illustrate the trends and activities in companion diagnostics partnering and dealmaking since 2009. The Appendix toward the end includes all the companion diagnostics deals since 2009 by company A-Z, deal type and therapy focus. Access the complete report at http://www.rnrmarketresearch.com/companion-diagnostics-partnering-terms-and-agreements-market-report.html.

Explore more reports on the diagnostics market at http://www.rnrmarketresearch.com/reports/life-sciences/diagnostics .

About Us:   

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
sales@rnrmarketresearch.com


SOURCE RnR Market Research